$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
How long does it take for crizotinib to be effective
2025-10-19 11:44:20
Check Details
Erlotinib first-line treatment of locally advanced or metastatic non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Will Crizotinib be reimbursed by medical insurance
2025-10-19 11:44:20
Check Details
How to take crizotinib and precautions
2025-10-19 11:44:20
Check Details
How much does the patient actually pay after crizotinib is reimbursed by medical insurance
2025-10-19 11:44:20
Check Details
Drugs for the treatment of lung cancer EGFR gene mutations: the first generation lung cancer targeted drug erlotinib
2025-10-19 11:44:20
Check Details
How much does a box of Erlotinib (Tarceva) cost after medical insurance reimbursement in 2021?
2025-10-19 11:44:20
Check Details
Will Crizotinib Capsules be included in the National Medical Insurance Directory in 2021
2025-10-19 11:44:20
Check Details
The effect of Dozerun in the treatment of patients with locally advanced or metastatic non-small cell lung cancer carrying EGFR gene mutations
2025-10-19 11:44:20
Check Details
How much does Dozerun (dacomitinib) cost per month after medical insurance in 2021?
2025-10-19 11:44:20
Check Details
Can Crizotinib Capsules be reimbursed by domestic medical insurance
2025-10-19 11:44:20
Check Details
The second-generation targeted drug for lung cancer, Dozerun, brings new options to patients with EGFR mutations
2025-10-19 11:44:20
Check Details
1
2
...
3901
3902
3903
3904
3905
3906
3907
...
4161
4162
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
2
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
3
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
4
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
5
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
6
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
7
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
8
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
9
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity
10
Tivozanib Dosing Guide for Renal Cell Carcinoma: 21-Day On/7-Day Off Cycle and Adjustments
11
Selpercatinib: Dosing and Administration Essentials of an Oral RET Inhibitor
12
Alpelisib: From Breast Cancer to PIK3CA-Related Overgrowth Spectrum